The Congenital Ichthyosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Ichthyosis pipeline products will significantly revolutionize the Congenital Ichthyosis market dynamics.
DelveInsight’s “Congenital Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congenital Ichthyosis, historical and forecasted epidemiology as well as the Congenital Ichthyosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Congenital Ichthyosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Congenital Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Ichthyosis Market Forecast
Some of the key facts of the Congenital Ichthyosis Market Report:
The Congenital Ichthyosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In August 2024, A year after investing in Timber Pharmaceuticals’ dermatology pipeline, Leo Pharma announced a Phase III setback for its lead asset, TMB-001. The topical isotretinoin ointment failed to show significant benefit in patients with moderate to severe congenital ichthyosis—a group of inherited skin disorders causing dry, scaly skin. In the Phase III ASCEND trial (NCT05295732), the treatment did not achieve statistically significant improvements over the vehicle, resulting in the failure to meet both primary and key secondary endpoints.
According to Ginarte et al., in the United States, a prevalence at birth of 1 per 100,000 population for Lamellar Ichthyosis (LI) and of 1 per 200,000 population for congenital Ichthyosiform Erythroderma (CIE) has been estimated.
As per the British Association of Dermatologists, Lamellar Ichthyosis is a rare form occurring in 1 in 200,000 live births in the United Kingdom
Key Congenital Ichthyosis Companies: Krystal Biotech, Timber pharmaceuticals, and others
Key Congenital Ichthyosis Therapies: KB105, TMB-001, and others
The Congenital Ichthyosis epidemiology based on severity-specific cases analyzed that about 2/3rd of the patients suffered from moderate to severe illness
Congenital Ichthyosis Overview
Ichthyosis is a group of keratinization disorders that is clinically and etiologically heterogeneous and characterized by dryness, flaking, and peeling of the skin. Due to abnormalities in the structure of the stratum corneum, the increased transepidermal water loss causes excessive dryness. There are congenital and acquired forms of the disease.
Congenital from of ichthyosis can be defined as a group of monogenetic disorders of cornification, sometimes associated with systemic symptoms.
Request a sample for the Triple X Syndrome Market Report: https://www.delveinsight.com/report-store/congenital-ichthyosis-market
Congenital Ichthyosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Download the report to understand which factors are driving Congenital Ichthyosis epidemiology trends @ Congenital Ichthyosis Epidemiology Forecast
Congenital Ichthyosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Ichthyosis market or expected to get launched during the study period. The analysis covers Congenital Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Congenital Ichthyosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Congenital Ichthyosis Therapies and Key Companies
KB105: Krystal Biotech
TMB-001: Timber pharmaceuticals
Discover more about therapies set to grab major Congenital Ichthyosis market share @ Congenital Ichthyosis Treatment Landscape
Congenital Ichthyosis Market Drivers
Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Congenital Ichthyosis
Population rates of Congenital Ichthyosis in children and young people have been investigated in several countries
Many therapies are under investigation in various phases of clinical trials. These include TMB-001, KB105
Congenital Ichthyosis Market Barriers
Challenges in Congenital Ichthyosis diagnosis
Development of novel Congenital Ichthyosis therapies
Limitations in gene therapy
Poor disease understanding
Clinical biomarkers
Scope of the Congenital Ichthyosis Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Congenital Ichthyosis Therapeutic Assessment: Congenital Ichthyosis current marketed and Congenital Ichthyosis emerging therapies
Congenital Ichthyosis Market Dynamics: Congenital Ichthyosis market drivers and Congenital Ichthyosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Congenital Ichthyosis Unmet Needs, KOL’s views, Analyst’s views, Congenital Ichthyosis Market Access and Reimbursement
To know more about Congenital Ichthyosis companies working in the treatment market, visit @ Congenital Ichthyosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Congenital Ichthyosis Market Report Introduction
2. Executive Summary for Congenital Ichthyosis
3. SWOT analysis of Congenital Ichthyosis
4. Congenital Ichthyosis Patient Share (%) Overview at a Glance
5. Congenital Ichthyosis Market Overview at a Glance
6. Congenital Ichthyosis Disease Background and Overview
7. Congenital Ichthyosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Congenital Ichthyosis
9. Congenital Ichthyosis Current Treatment and Medical Practices
10. Congenital Ichthyosis Unmet Needs
11. Congenital Ichthyosis Emerging Therapies
12. Congenital Ichthyosis Market Outlook
13. Country-Wise Congenital Ichthyosis Market Analysis (2019–2032)
14. Congenital Ichthyosis Market Access and Reimbursement of Therapies
15. Congenital Ichthyosis Market Drivers
16. Congenital Ichthyosis Market Barriers
17. Congenital Ichthyosis Appendix
18. Congenital Ichthyosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: 14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
